Today: 20 May 2026
Browse Category

NYSE:NVO 7 December 2025 - 5 January 2026

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk is cutting Wegovy prices in China, with local reports citing 48% reductions for the highest doses in Yunnan and Sichuan. The move comes as the company faces a 2026 patent expiry for semaglutide and rising competition from Chinese drugmakers. Novo shares fell after the China pricing news circulated. The company did not disclose exact new prices in its statement.
30 December 2025
·
Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

The U.S. FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP-1 drug for chronic weight management, on Dec. 22. Novo Nordisk ADRs closed at $52.56 on Dec. 24, up 1.8% after the news. The company plans a U.S. launch in early January 2026. Trial data showed a mean weight loss of 16.6% for patients adhering to the regimen.
25 December 2025
·
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly shares rose 0.47% to $1,076.67 in light Christmas Eve trading, with volume just over 200,000 shares by late morning. Investors focused on new GLP-1 headlines, including regulatory updates and global expansion, as well as a Reuters report showing Lilly’s Mounjaro outpacing Novo’s Wegovy in India since March. Indian generics are expected to intensify competition as patent expiries approach.
24 December 2025
···
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

U.S. regulators have approved Novo Nordisk’s oral Wegovy pill for weight management and cardiovascular risk reduction, sending NVO shares higher earlier this week. Analysts are watching pricing and insurance coverage in the U.S., as well as competition in India ahead of 2026 generic launches. The pill is expected to reach U.S. patients in January. NVO stock traded in the low-$50s on Dec. 24.
24 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly shares closed down 0.45% at $1,071.64 on Tuesday after the FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP‑1 drug for chronic weight management in the U.S. Novo shares rose on the news, while Lilly stock traded flat in after-hours. Investors focused on the competitive impact of the new oral treatment on Lilly’s obesity franchise. Trading volume reached about 2 million shares.
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly shares hovered near record highs Tuesday after the FDA approved Novo Nordisk’s first oral Wegovy pill, intensifying rivalry in the obesity drug market. LLY traded around $1,077 as investors weighed Novo’s launch against Lilly’s own oral candidate, orforglipron, which could reach the market in 2026. Both firms have signaled lower pricing for new pills as competition heats up.
23 December 2025
···
Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

U.S. regulators approved Novo Nordisk’s once-daily oral Wegovy pill for chronic weight management and cardiovascular risk reduction on Dec. 23, 2025. Novo shares rose about 9% in U.S. trading, with investors reacting to the company’s first-to-market status for a high-efficacy oral GLP-1 obesity drug. The FDA decision also lifted European healthcare stocks, pushing the STOXX 600 to a record high.
23 December 2025
·
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly shares traded near $1,076 after the FDA approved Novo Nordisk’s first daily oral Wegovy for obesity. Novo plans a U.S. launch in January 2026, beating Lilly’s own oral candidate, which remains under review. Novo shares rose on the news; Lilly slipped slightly. Analysts expect oral obesity drugs could reach 20% of the market by 2030.
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

The FDA approved Novo Nordisk’s oral Wegovy pill for chronic weight management in the U.S., marking the first oral GLP-1 agonist cleared for this use. Shares jumped on the news, lifting European healthcare stocks. The company reported 16.6% mean weight loss in trials when taken as prescribed. Novo plans to launch the pill in the U.S. in early January 2026.
23 December 2025
···
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

The FDA approved Novo Nordisk’s once-daily Wegovy pill (oral semaglutide 25 mg) for chronic weight management and reducing cardiovascular risk in adults with obesity or overweight on December 22, 2025. The company plans a U.S. launch in January 2026 at $149 per month for eligible patients. Clinical trials showed average weight loss of 13.6% to 16.6% depending on adherence.
23 December 2025
··
Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly shares closed up 0.47% at $1,076.48 Monday, then fell about 1% in after-hours trading after the FDA approved Novo Nordisk’s Wegovy weight-loss pill. Novo’s U.S. shares jumped roughly 6% following the news. The new oral semaglutide is the first FDA-cleared pill for obesity, with Novo saying it will launch early next year at $149 a month. Lilly’s own oral obesity drug, orforglipron, could be approved as soon as late March.
23 December 2025
····
Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly shares closed up 1.45% at $1,056.88 Thursday after reporting positive Phase 3 results for its oral obesity drug orforglipron. Patients switching from injectable GLP-1 drugs maintained weight loss, with those from Wegovy averaging 0.9 kg change and those from Zepbound 5 kg. The stock held steady in after-hours trading. Detailed trial data will be released later.
18 December 2025
···
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk shares have dropped about 45% in 2025 and over 50% from their 2024 peak, following profit warnings, slower GLP-1 growth, and a failed Alzheimer’s trial. The stock now trades near $47.9, down sharply after the EVOKE and EVOKE+ studies showed no significant benefit for semaglutide in early Alzheimer’s. Revenue in Q3 2025 rose 5% to DKK 74.98 billion, missing analyst expectations.
7 December 2025
··
1 2 3 4 5 6 7

Stock Market Today

  • NVIDIA Options Signal 6.1% Post-Earnings Price Move
    May 20, 2026, 1:57 PM EDT. NVIDIA (NVDA) options trading before earnings shows normal volumes, with call options outnumbering puts by over two to one. Implied volatility, a measure of expected stock price fluctuations derived from option prices, indicates the market expects a significant move around 6.1%, roughly $13 per share, following the earnings report. This level of implied volatility reflects investor anticipation of substantial price action, influenced by earnings results and company outlook. Such expectations guide traders on potential market reactions and inform hedging strategies ahead of NVIDIA's earnings announcement.

Latest articles

BlackBerry Stock Nears Highs as Traders Eye Government Moves

BlackBerry Stock Nears Highs as Traders Eye Government Moves

20 May 2026
BlackBerry’s U.S.-listed shares rose 0.5% to $6.24 after its AtHoc platform renewed a high-level U.S. government cloud-security certification. Trading volume topped 27 million shares, with prices ranging from $6.10 to $6.37. The company’s QNX business reported 20% revenue growth last quarter. Executives are scheduled to speak at a Toronto tech conference Thursday.
Archer Aviation Swings as New SEC Filings Put Spotlight Back on Cash Burn

Archer Aviation Swings as New SEC Filings Put Spotlight Back on Cash Burn

20 May 2026
Archer Aviation shares were flat near $5.94 Wednesday afternoon as SEC filings showed executives sold stock to cover tax withholding on vested shares. The company registered over 3.2 million shares for resale and plans to issue up to $8 million in stock to vendors. Archer reported a $217.7 million net loss in Q1 and ended the quarter with $1.8 billion in liquidity.
IREN Stock Surges as Nvidia Fever Returns — But the AI Cloud Bet Has a Catch

IREN Stock Surges as Nvidia Fever Returns — But the AI Cloud Bet Has a Catch

20 May 2026
IREN Limited shares rose 9.4% to $52.23 on Wednesday, trading over 23 million shares as investors awaited Nvidia’s earnings. IREN recently signed a $3.4 billion AI cloud contract with Nvidia and closed a $3 billion convertible-note offering. The company reported a quarterly net loss of $247.8 million on revenue of $144.8 million, down from the prior quarter.
Go toTop